Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Aprea Therapeutics
(NASDAQ:APRE)
Intraday
$5.94
0.59
[11.03%]
After-Hours
$5.94
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$5.94
0.59
[11.03%]
At close: Apr 12
$5.94
0
[0.00%]
After Hours: 5:47PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Aprea Therapeutics Stock (NASDAQ:APRE)
Aprea Therapeutics Stock (NASDAQ: APRE)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, April 10, 2024
Aprea Therapeutics Announces Presentations On Its Next Generation WEE1 Inhibitor, APR-1051, And A Novel Macrocyclic ATR Inhibitor, ATRN-119, At AACR Annual Meeting 2024
Benzinga Newsdesk
-
Apr 10, 2024, 12:02PM
Thursday, April 04, 2024
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights
-
Apr 4, 2024, 8:09AM
Wednesday, March 27, 2024
Wedbush Maintains Outperform on Aprea Therapeutics, Raises Price Target to $11
Benzinga Newsdesk
-
Mar 27, 2024, 7:54AM
Tuesday, March 26, 2024
HC Wainwright & Co. Maintains Buy on Aprea Therapeutics, Maintains $20 Price Target
Benzinga Newsdesk
-
Mar 26, 2024, 11:12AM
Aprea Therapeutics: Q4 Earnings Insights
Benzinga Insights
-
Mar 26, 2024, 9:10AM
Monday, March 11, 2024
Why Is Precision Oncology-Focused Aprea Therapeutics Stock Trading Higher On Monday?
Vandana Singh
-
Mar 11, 2024, 9:39AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights
-
Mar 11, 2024, 9:05AM
Market-Moving News for March 11th
Benzinga Newsdesk
-
Mar 11, 2024, 8:40AM
Aprea Therapeutics shares are trading higher after the company announced FDA Clearance of its IND for APR-1051. The company also announced private placement financing of up to $34 million.
Benzinga Newsdesk
-
Mar 11, 2024, 8:38AM
Aprea Therapeutics Announces Private Placement Financing Of Up To $34M
Benzinga Newsdesk
-
Mar 11, 2024, 8:32AM
Aprea Therapeutics Announces FDA Clearance Of IND For APR-1051, Its Next Generation WEE1 Kinase Inhibitor For Cyclin E Overexpressing Cancers
Benzinga Newsdesk
-
Mar 11, 2024, 8:30AM
Tuesday, February 06, 2024
Aprea Therapeutics Announces Submission Of IND Application For APR-1051, A Next Generation WEE1 Kinase Inhibitor
Benzinga Newsdesk
-
Feb 6, 2024, 8:03AM
Friday, January 26, 2024
Aprea Therapeutics Entered Into An At-market Offering Agreement With H.C. Wainwright Under Which They May Offer And Sell Up To $1M Of Common Stock From Time To Time
Charles Gross
-
Jan 26, 2024, 7:22AM
Thursday, January 04, 2024
Aprea Therapeutics Provided A Corporate Update Highlighting Recent Developments And Plans For Advancement Of Its Pipeline Of DNA Damage Response Anti-Cancer Agents In 2024
Benzinga Newsdesk
-
Jan 4, 2024, 4:12PM
Thursday, November 09, 2023
Aprea Therapeutics Q3 EPS $(0.86) Beats $(1.16) Estimate, Sales $319.47K Beat $80.00K Estimate
Benzinga Newsdesk
-
Nov 9, 2023, 5:27PM
Wednesday, November 01, 2023
HC Wainwright & Co. Reiterates Buy on Aprea Therapeutics, Maintains $20 Price Target
Benzinga Newsdesk
-
Nov 1, 2023, 6:59AM
Monday, October 30, 2023
A Look Into Healthcare Sector Value Stocks
Benzinga Insights
-
Oct 30, 2023, 10:43AM
Monday, October 16, 2023
Aprea Unveils Initial Clinical Data On ATRi, ATRN-119, And Pre-Clinical Data On WEE1i, ATRN-1051, At AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio
Benzinga Newsdesk
-
Oct 16, 2023, 8:45AM
Monday, September 25, 2023
5 Value Stocks To Watch In The Healthcare Sector
Benzinga Insights
-
Sep 25, 2023, 10:44AM
Wednesday, September 13, 2023
HC Wainwright & Co. Reiterates Buy on Aprea Therapeutics, Maintains $20 Price Target
Benzinga Newsdesk
-
Sep 13, 2023, 6:30AM
Monday, September 11, 2023
Aprea Therapeutics Says Updated Preclinical Data For ATRN-105 For Ovarian Cancer, Demonstrated That The Selective Properties Of ATRN-1051 May Make It A More Efficacious Cancer Therapy Than The Other Wee1 Inhibitors In Development
Benzinga Newsdesk
-
Sep 11, 2023, 8:14AM
Monday, September 04, 2023
5 Value Stocks To Watch In The Healthcare Sector
Benzinga Insights
-
Sep 4, 2023, 10:44AM
Friday, August 25, 2023
Director at Aprea Therapeutics Acquires Company Stock Options Worth 12,500 Shares
Benzinga Insights
-
Aug 25, 2023, 11:00AM
Thursday, August 24, 2023
Aprea Therapeutics Names Richard Peters As Chairman, Replacing Christian Schade, Who Is Stepping Down From Board
Benzinga Newsdesk
-
Aug 24, 2023, 7:33AM
Thursday, August 10, 2023
HC Wainwright & Co. Reiterates Buy on Aprea Therapeutics, Maintains $20 Price Target
Benzinga Newsdesk
-
Aug 10, 2023, 12:03PM
Tuesday, July 18, 2023
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Insights
-
Jul 18, 2023, 5:32PM
Friday, June 09, 2023
Satsuma Pharmaceuticals And 2 Other Penny Stocks Insiders Are Aggressively Buying
Lisa Levin
-
Jun 9, 2023, 7:30AM
Wednesday, May 24, 2023
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
-
May 24, 2023, 12:49PM
Tuesday, May 16, 2023
HC Wainwright & Co. Reiterates Buy on Aprea Therapeutics, Maintains $20 Price Target
Benzinga Newsdesk
-
May 16, 2023, 6:23AM
Aprea Therapeutics Q1 EPS $(1.34) Up From $(7.20) YoY
Happy Mohamed
-
May 16, 2023, 12:19AM
Friday, April 07, 2023
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights
-
Apr 7, 2023, 9:06AM
Monday, April 03, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Apr 3, 2023, 1:36PM
Thursday, March 30, 2023
Aprea Therapeutics Q4 EPS $(0.92) Beats $(2.60) Estimate
Bill Haddad
-
Mar 30, 2023, 4:45PM
Monday, March 27, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Mar 27, 2023, 1:22PM
Friday, March 24, 2023
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
-
Mar 24, 2023, 12:05PM
Friday, March 10, 2023
Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2023
Benzinga Insights
-
Mar 10, 2023, 10:00AM
Maxim Group Initiates Coverage On Aprea Therapeutics with Buy Rating, Announces Price Target of $16
Benzinga Newsdesk
-
Mar 10, 2023, 9:17AM
Wednesday, March 01, 2023
Aprea Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
Happy Mohamed
-
Mar 1, 2023, 4:55PM
Thursday, February 23, 2023
Why Aprea Therapeutics Shares Hit A New 52-Week Low Today
Henry Khederian
-
Feb 23, 2023, 9:29AM
Aprea Therapeutics shares are traidng lower after the company announced pricing of a $5.5 million underwritten public offering of common stock,
Benzinga Newsdesk
-
Feb 23, 2023, 9:17AM
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights
-
Feb 23, 2023, 8:06AM
Reported Late Wednesday Feb 22, Aprea Therapeutics Announces Pricing Of $5.5M Underwritten Public Offering Of 1.05M Shares Of Common Stock At A Price Of $5.25/Share
Happy Mohamed
-
Feb 23, 2023, 12:22AM
Wednesday, February 22, 2023
Aprea Therapeutics Announces Proposed Public Offering Of Common Stock, Terms Not Disclosed
Michael Horton
-
Feb 22, 2023, 5:13PM
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights
-
Feb 22, 2023, 4:31PM
Wednesday, February 15, 2023
Aprea Therapeutics Received An Award Notification From The National Cancer Institute Of Around 2M Over Two Years For Combination Of DNA Damage Response Inhibitors For High-grade Serous Ovarian Cancer
Benzinga Newsdesk
-
Feb 15, 2023, 8:19AM
Monday, February 13, 2023
Aprea Therapeutics Announces One-for-Twenty Reverse Stock Split, Which Became Effective Feb. 10
Bill Haddad
-
Feb 13, 2023, 7:12AM
Monday, January 30, 2023
Aprea Therapeutics Appoints John Hamill As Chief Financial Officer
Bill Haddad
-
Jan 30, 2023, 8:12AM
Thursday, January 19, 2023
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights
-
Jan 19, 2023, 4:30PM
Wednesday, January 11, 2023
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights
-
Jan 11, 2023, 8:05AM
Aprea Therapeutics Announces Dosing Of First Patient In Phase 1/2a Clinical Trial Of Oral ATR Inhibitor ATRN-119 For The Treatment Of Advanced Solid Tumors
Benzinga Newsdesk
-
Jan 11, 2023, 8:05AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch